University of Michigan Comprehensive Cancer Center, 1500 East Medical Center Drive, Room 6302, Ann Arbor, Michigan 48109, USA.
J Clin Invest. 2013 Feb;123(2):563-5. doi: 10.1172/JCI67460. Epub 2013 Jan 25.
There is increasing evidence that prostate cancers in rodent models and in men contain a cellular subpopulation that displays stem cell properties. These prostate cancer stem cells (PCSCs) lack androgen receptor expression and are increased in castration-resistant disease. In this issue of the JCI, a study from Yoshioka et al. demonstrates that PCSCs are regulated by a pathway in which α6β4 integrin amplifies signaling through ErbB2 and c-Met receptors. Targeting this pathway provides a novel therapeutic strategy for hormone refractory prostate cancer.
越来越多的证据表明,啮齿动物模型和男性中的前列腺癌中存在具有干细胞特性的细胞亚群。这些前列腺癌干细胞(PCSCs)缺乏雄激素受体表达,并在去势抵抗性疾病中增加。在本期 JCI 中,Yoshioka 等人的研究表明,PCSCs 受 α6β4 整联蛋白调节,该途径通过 ErbB2 和 c-Met 受体放大信号。靶向该途径为激素难治性前列腺癌提供了一种新的治疗策略。